Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 91 for your search:
Drug:
anti-thymocyte globulin
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
SCT 0208
, NCT00679536
2.
Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
3.
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
EudraCT:2005-000805-68
, NCT00354120
4.
Phase II/III Randomized Study of High-Dose Immunosuppressive Therapy Comprising Total-Body Irradiation, Cyclophosphamide, and Anti-Thymocyte Globulin Followed By Autologous CD34+ Hematopoietic Stem Cell Transplantation Versus High-Dose Pulse Cyclophosphamide in Patients With Severe Systemic Sclerosis
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
NCI
Protocol IDs:
FHCRC-1948.00
, FHCRC-1948.00, NCT00114530, SCOT
5.
To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
230704-HMO-CTIL
, NCT00226512
6.
Phase III Study of Induction and Maintenance Therapy Comprising Etoposide, Dexamethasone, and Cyclosporine Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Inherited or Severe and Persistent Secondary Hemophagocytic Lymphohistiocytosis
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
CCLG-LCH-2006-02
, EU-20619, UKCCSG-HLH-2004, EUDRACT-2005-002187-28, NCT00334672
7.
Phase III Randomized Study of Conventional Combination Chemotherapy With Versus Without Gemtuzumab Ozogamicin in Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 30
Sponsor:
NCI
Protocol IDs:
COG-AAML0531
, AAML0531, NCT00372593
8.
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
PROGAST
, NCT00180089
9.
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
65 and under
Sponsor:
Other
Protocol IDs:
2005-0366
, NCT00469144
10.
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
50 to 75
Sponsor:
NCI, Other
Protocol IDs:
SU-11122007-874
, 97843, BMT190, NCT00568633, NCT00568633
11.
Chronic Graft-Versus-Host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-Identical Siblings in Patients With Acute Leukemia
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
ATGFamilyStudy
, NCT00678275
12.
Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Older patients
Sponsor:
NCI, Other
Protocol IDs:
BMT124
, 75117, BMT124, NCT00185692, NCT00185692
13.
Phase I/II Study of a Myeloablative Conditioning Regimen Comprising Cyclophosphamide, Anti-thymocyte Globulin, and Total-Body Irradiation in Patients With Severe Aplastic Anemia Undergoing Related or Unrelated Umbilical Cord Blood Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
40 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-2030.00
, 6169, NCT00354419
14.
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for AML and MDS
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
2005-0508
, NCT00402558
15.
Fludarabine-Based Conditioning for Severe Aplastic Anemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI, NHLBI
Protocol IDs:
383
, BMT CTN 0301, 5 U01 HL69294-05, NCT00326417
16.
Prophylactic Transfer of Leukemia-Reactive T Cells After Allogeneic Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
EK126092000
, NCT00460629
17.
Autologous Followed by Non-Myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
BMT185
, 97623, BMT185, NCT00481832, NCT00481832
18.
Phase I/II Study of Preparative Cytoreductive Therapy Comprising Cyclophosphamide, Fludarabine Phosphate, and Antithymocyte Globulin Followed By T-Cell Depleted, Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 60
Sponsor:
NCI
Protocol IDs:
UMN-2007BMT031
, UMN-2007BMT031, MT2000-09, NCT00630253
19.
Phase I/II Pilot Study of High-Dose Immunosuppressive Therapy Comprising Carmustine, Etoposide, Cytarabine, and Melphalan in Combination With Anti-Thymocyte Globulin Followed by Syngeneic or Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe, Refractory Autoimmune Neurologic Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-2260.00
, 6733, FHCRC-IR-6733, NCT00716066
20.
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
CCI #07-00119
, CHLA-#07-00119, NCT00730314
21.
Double Cord Blood Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
Other
Protocol IDs:
CHNY-06-533
, IRB AAAC3457, NCT00801931
22.
Autologous and Allogeneic Transplant for Relapsed Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
30 and under
Sponsor:
Other
Protocol IDs:
CHNY-01-501
, AAAA5185, NCT00802113
23.
Plerixafor and Granulocyte Colony-Stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
2007-0772
, NCT00822770
24.
Phase II Study of HLA-Matched Nonmyeloablative Peripheral Blood Stem Cell Transplantation Followed By Allogeneic T-Cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
NHLBI
Protocol IDs:
NHLBI-97-H-0196
, NCT00003553
25.
Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Disease or Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
8 to 80
Sponsor:
NHLBI
Protocol IDs:
NHLBI-99-H-0050
, NCT00003838
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute